SCHEMBL24923066

SCHEMBL24923066

CNCCCn1nnc(-c2ccc(Br)cn2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 1/20 0.37
▸ MMP2 P08253 1/20 0.37
▸ MMP3 P08254 1/20 0.37
▸ MMP7 P09237 1/20 0.37
▸ MMP9 P14780 1/20 0.37
▸ MMP8 P22894 1/20 0.37
▸ MMP13 P45452 1/20 0.37
▸ S1PR2 O95136 1/20 0.36
▸ S1PR1 P21453 1/20 0.36
▸ S1PR3 Q99500 1/20 0.36
▸ LPAR2 Q9HBW0 1/20 0.36
▸ USP2 O75604 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25808664 0.85 RAB9A (0.43) MMP1MMP2MMP3MMP7MMP9
SCHEMBL24142430 0.83 LTA4H (0.46) MMP1MMP2MMP3MMP7MMP9
SCHEMBL25808654 0.82 SMN1; SMN2 (0.47) ALDH1A1NPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL25760237 0.82 MMP1 (0.35) MMP1MMP2MMP3MMP7MMP9
SCHEMBL25809729 0.80 MCHR1 (0.36) MMP1MMP2MMP3MMP7MMP9
SCHEMBL4485447 0.80 MAOB (0.44) HDAC6
SCHEMBL24143107 0.80 LTA4H (0.47) USP2ALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL24143181 0.79 CPB2 (0.41) MMP1MMP2MMP3MMP7MMP9
SCHEMBL30768239 0.79 LMNA (0.47) NPC1RAB9ASMN1; SMN2LMNAKMT2A
SCHEMBL23500484 0.79 LMNA (0.47) NPC1RAB9ASMN1; SMN2LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11566023-B2 Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof AKAGERA MEDICINES, INC. (US) 2023-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11566023-B2 Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof OXA1L, THPO, TBCD MMP1 4195/4885MMP2 3947/4885MMP3 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback